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There is now ample evidence that homotransplantation of whole vital 
organs will be a useful and increasingly important method of therapy in 
the coming years. The attitude of gloom with which both physicians and 
basic scientists viewed this possibility only recently has been replaced by 
a sometimes unbridled optimism. 
The principal reasons for this change have been the demonstrations 
that many uremic patients can be materially benefited by homotransplan- 
tation of the kidney, that rejection is an inherently and often easily re- 
versible phenomenon, that the need for stringent in~munosuppressive 
therapy tends to decrease with the passage of time, and that the patient 
with a really good result can live an essentially normal life. 
I. PAST EFFORTS 
The facts mentioned above became evident soon after the now widely 
used combination of immunosuppressive drugs was evolved. Using most 
importantly azathioprine and prednisone, and in some cases actinomycin 
C and local homograft irradiation, 64 patients were treated in Denver 
from November 1962 to March 1964, employing homografts from volun- 
teer living donors. Today, now 2 M to almost 4 years later, exactly half of 
these recipients are still alive by virtue of their still chronically function- 
ing kidneys. The principal mortality was during the first few postoperative 
months (Fig. l), after which the chance of continuing survival was 
relatively good. 
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There was a striking difference in the results, depending upon the 
source of the homograft. Forty-six of the foregoing recipients received 
kidneys from consanguineous donors; 29 (63%) are still alive. In contrast, 
only 3 of 18 patients who received nonrelated kidneys survive to date 
(Fig. 2). 
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FIG. 1. Life survival curve of the first sixty-four patients who received renal homo- 
transplants from November 1962 to March 1964. All donors were living volunteers. The 
recipients now have been followed for 2 %  to almost 4 years. Exactly half of the patients 
were still alive on September 26, 1966. 
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FIG. 2. A breakdown of the results shown in Fig. 1 according to the source of the homo- 
graft. Note that 63% of the patients who had consanguineous donors are still alive com- 
pared to only 3 of 18 who received nonrelated kidneys. 
This experience was accumulated at a time when the clinical problems 
which were to be encountered were either understood poorly or not at all. 
Studies on Transplantation 353 
Nevertheless, the substantial salvage rate obtained has proved in prin- 
ciple the feasibility of the undertaking. Furthermore, these, as well as 
similar results from other institutions (Hamburger et al., 1965; Hume 
et al., 1966; Murray et al., 1965; Straffon et al., 1966), have defined areas 
into which intensive effort has already been invested. 
11. CAUSES OF FAILURE 
The vast majority of deaths after renal homotransplantation are more 
or less directly caused by the immunosuppressive agents used whether 
this occurs early, at an intermediate time, or late. In turn, the toxicity 
of the various agents is related to the difficulty with which rejection is 
controlled. 
A pertinent example is shown in Fig. 3. The patient, who received a 
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FIG. 3.  Typical unsuccessfully treated case. The donor and recipient were brothers, 
both of A+ blood type. A violent rejection crisis followed good early function, and anuria 
developed which lasted 2 weeks. Although the rejection was reversed and a secondary 
diuresis began, the patient died from drug toxicity, leukopenia, and septicemia. Acti C, 
each arrow is 200 pg intravenous actinomycin C. (By permission of Surgery 56,296, 1964.) 
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kidney from his brother, had good renal function for more than week. 
Severe rejection then ensued, causing temporary renal shutdown, but 
with maximum immunosuppression, urinary output resumed. In spite of 
this temporary improvement, the patient died shortly afterward of fungal 
and bacterial sepsis which were primarily the consequence of bone 
marrow depression. The responsible drug was azathioprine. It has since 
been appreciated that the dose of this agent must be reduced during 
periods of depressed urine excretion inasmuch as the drug has an im- 
portant renal pathway of detoxification. Dose control is extremely 
difficult under these circumstances. 
With increased experience, such deaths from acute bone marrow 
depression have become rare, and it seems probable that azathioprine is 
the safest of the immunosuppressive drugs being used for chronic therapy. 
When azathioprine can be used as the sole therapeutic agent, infectious 
complications or other morbidity are negligible. Unfortunately, this is 
frequently not possible. It is often found that continued homograft func- 
tion can be maintained only with the additional use of substantial quanti- 
ties of prednisone. It is the need for high dose steroid therapy which most 
severe6 limits the life expectancy of any individual patient. 
The tragic consequences which may ensue during steroid therapy, 
either early or late, are illustrated in Fig. 4. This patient, who had a 
severe late rejection almost a year after operation, needed large doses of 
prednisone to prevent further deterioration of homograft function. As a 
consequence, he developed typical cosmetic deformities, bone de- 
mineralization, a duodenal ulcer, pancreatitis, and parenchymal liver 
disease. Until the time of death, his renal function was adequate to sustain 
life in a normal person. At autopsy, he had pneumonitis and infestation of 
several organ systems with cytomegalic inclusion virus. Such patients 
often become infected with fungi or bacteria which ordinarily have a low 
grade pathogenicity. 
111. HISTOCOMPATIBILITY MATCHING 
Since toxicity from immunosuppression accounts for a heavy mortality, 
usually because large doses are mandatory, intensive efforts are being 
made in several centers to sharpen the criteria by which a donor is 
decided upon for any given recipient. With proper selection, it would be 
expected that the need for potentially lethal immunosuppressive measures 
could be at least partially eliminated. This approach has been evaluated in 
collaboration with Dr. Paul Terasaki of Los Angeles, whose method of 
lymphocyte analysis appears to measure something which is at least 
related to histocompatibility antigens (Porter et al., 1966; Terasaki 
et al., 1966). 
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The fate of the first 26 patients for whom donors were chosen by 
Terasaki on the basis of the best available antigen match is shown in 
Fig. 5. The transplantations were between blood relatives in half the 
cases, and between nonrelated pairs in the other half. After a follow-up 
of 12 to 22 months, the results were exactly the same in the two sub- 
groups. The upgrading was expected in the unrelated subgroup if the test 
had any discriminatory capability. Failure to increase survival in recip- 
ients of related kidneys was a disappointment. The drug toxicity described 
earlier was still the chief cause of death in both groups. It became clear 
that the high mortality could not be eliminated even with effective 
typing procedures without the evolution of better immunosuppressive 
treatmen.t. 
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FIG. 5. Results of renal transplantation in a more recent series of patients whose donors 
were selected by Terasaki's antigen matching method. Note that survival after 13-22 months 
was exactly the same in both the related and nonrelated cases. Compare these results with 
those shown in Fig. 2. 
IV. IMPROVED IMMUNOSUPPRESSION 
The most promising new treatment we have used is antilymphoid 
serum, raised in a heterologous host by immunization with lymphoid 
tissue from the species to be eventually treated. Such a product was 
described by Metchnikoff in 1899 and by numerous others in the ensuing 
60 years. Its use to potentiate homograft survival was first suggested by 
Woodruff (1 960; Woodruff and Anderson, 1964) and Waksman et al. 
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(1961). The value of antilymphoid serum for this purpose has been 
established in a number of subsequent studies (Gray et al., 1964; Jeejeeb- 
hoy, 1965; Levey and Medawar, 1966a,b; Monaco et al., 1965, 1966; 
Nagaya and Sieker, 1965). 
In our laboratories, antilymphoid derivatives have been developed for 
use in both dogs and man (Iwasaki et al., 1967). Horses were sub- 
cutaneously immunized with lymphocytes from the spleen, lymph nodes, 
or thymus of the appropriate species. The equine leukoagglutinin and 
lymphoagglutinin titers rose to as high as 1 : 16,000 (Fig. 6). The horse 
sehm which was toxic in its raw state was absorbed with pooled red 
cells and serum of the species which provided the immunizing tissue. 
FIG. 6. Effect of immunizing dose upon the leukoagglutinin titer of a horse inoculated 
with cadaveric human lymphoid tissue. Note that the rise in titer was very modest during 
the first 3 months, during which time small doses of cells were used. When the quantity 
of antigen was increased by the use of spleen cells, abrupt increases in titer were observed 
within a few days. (From Iwasaki et al., 1967.) 
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Next, studies were conducted to localize the desired antibody (Iwasaki 
et al., 1967). By separation with the DEAE cellulose column, and by 
determination of the leukoagglutinating titers and electrophoretic char- 
acteristics of the various eluates, it was found that the antiwhite cell 
antibody was chiefly in Y-globulin with lesser activity in /3-globulin (Fig. 
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7). These constituents could easily be removed by double or quadruple 
precipitation with 0.4 saturation ammonium sulfate (Fig. 8). 
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FIG. 7. Studies of the leukoagglutinin-containing fractions in antihuman-lymphoid serum 
employing column chromatography, electrophoresis, and immunoelectrophoresis. The 
various eluates from the DEAE cellulose column were analyzed spectrophotometrically for 
protein content (expressed as optical density), and the presence or absence of leuko- 
agglutinins determined for each collection tube. The electrophoresis and immunoelectro- 
phoresis permitted relatively complete classification of the active immunoglobulins. (From 
Iwasaki et al., 1967.) 
Ammonium sulfate-precipated antidog-lymphoid globulin has been 
extensively studied in the laboratory (Iwasaki et al., 1967; Starzl et al., 
1967). When administered subcutaneously as the sole therapy, it pro- 
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FIG. 8. Electrophoresis and immunoelectrophoresis of absorbed antihuman-lymphoid 
serum and the protein obtained from it by four precipitations with 0.4 saturated ammonium 
sulfate, four dialyses and lyophilization. The final product, which was used clinically, con- 
sists almost entirely of y G globulin. (From Iwasaki et al., 1967.) 
longed the survival of either kidney or liver homografts (Fig. 9) only 
slightly less than azathioprine (Starzl et al., 1967). There was little overt 
toxicity although a substantial fraction of either control or transplanted 
kidneys developed electron-dense bodies in the glomeruli (Iwasaki et 
al., 1967) which did not cause a demonstrable reduction in function. The 
studies indicated that the immune globulin was relatively safe, at least 
for short-term therapy, but that it was not potent enough to warrant use 
as the sole method of immunosuppression. 
For clinical trial, antihuman-lymphoid globulin was therefore com- 
bined with the older standard drugs, azathioprine and prednisone (Starzl 
et al., 1967). As in the past, a conscious effort was made to use as little 
prednisone as possible. Eight patients were treated from 9 weeks to 3 
months ago. Their renal function, drug doses, and peripheral hematologic 
patterns during the first 9 postoperative weeks were then compared to 
those of three groups of previously treated recipients in which the homo- 
graft sources had been comparable. 
The results are shown in Fig. 10. During the period in question, only 
46% as much prednisone was required as for any of the preceding series. 
The renal function was comparable. The peripheral lymphocytes were 
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FIG. 9. Course of a dog after orthotopic liver transplantation. The donor and recipient 
were nonrelated mongrel animals. The only immunosuppression used was horse anti- 
lymphoid serumgiven intraperitoneally. This treatment was stopped 3 weeks postoperatively 
and the animal has lived for more than 5 subsequent months during all of which time the 
peripheral lymphocyte count has been high. (From Starzl et al., 1967.) 
little changed, a finding which is consonant with the brilliant studies of 
Levey and Medawar (1966a,b) who have shown that the immuno- 
suppressive effect is not dependent upon either lymphoid depletion or 
lymphopenia. All eight patients are clinically well. 
The aforementioned studies are purely investigational. Whether long- 
term toxicity, including foreign protein injury to the homograft itself, 
will occur, can only be determined with longer follow-up. These data do 
indicate, however, that the possibility of better immunosuppression is not 
just a mirage. 
V. OTHER ORGANS 
Clinically, only the kidney has been transplanted successfully to date. 
It seems inevitable that other organs will follow. In our laboratories, dogs 
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FIG. 10. Variations in immunosuppression and renal function during the first 63 post- 
operative days in four successive groups of patients who received kidneys from blood 
relatives.. Since the blood urea nitrogen and creatinine clearance were not determined each 
day, these were compiled on a weekly basis. Those in series 4 received adjuvant therapy 
with antilymphoid globulin. Note the drastic reduction in average prednisone dose which 
was achieved in these patients without significant loss of renal function. (From Starzl et al., 
1967.) 
are alive as long as 2% years after complete hepatectomy and replace- 
ment with a homograft from a nonrelated mongrel donor (Starzl et al., 
1965). In our experience, this kind of chronic survival can be achieved 
more often with hepatic than with renal homografts. Other workers have 
had long-term success with cardiac and pulmonary homotransplantation. 
VI. SUMMARY 
Results with clinical renal homotransplantation have been reviewed. 
The patterns of mortality have been cited as these relate to research in 
histocompatibility typing and in the search for better immunosuppressive 
regimens. 
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DISCUSSION 
DR. BERENBAUM: Have you any information on the susceptibility to infections of dogs 
or patients treated with antilymphocyte sera as compared with conventionally treated cases? 
DR. STARZL: We do not have a precise quantitative evaluation in this respect as we do in 
patients with Irnuran and prednisone. We have had no infections in patients treated with 
immune globulin and, in animals, infections have not been a prominent cause of failure. The 
patients are extraordinarily well off after treatment with antilymphoid globulin given in 
combination with azathioprine and small doses of steroids. 
DR. AMOS: What is really known about the physiological adaptation to immunosup- 
pressive drugs? The patients starting off on azathioprine are often in a very unstable position 
from the beginning. As you pointed out, in dogs one can stop drug treatment at  a certain 
time after grafting, and an adaptation seems to occur between the transplant and the host. 
There may be also an adaptation of the host to the drug, and if we knew exactly what the 
individual drug requirements of a patient were, I think this might help in reducing initial 
mortality. 
DR. STARZL: Yes, it would help very much, because there is a great individual difference. 
Some patients can tolerate only 0.5 mglkg and some 4 or 5 mglkg. 
DR. BACH: I t  was encouraging to see the survival of kidneys from unrelated donors 
matched by leukocyte typing as compared to the survival of those from related donors that 
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you observed. I wonder how easy it was to find the unrelated donors who matched to the 
degree that they were matched. 
DR. STARZL: The results obtained earlier with randomly selected related donors were 
quite good and were not significantly improved by matching according to leukocyte typing. 
Very often, within the related group, there is not a large number of people from whom to 
select and therefore the quality of the match cannot be significantly improved by leukocyte 
typing. Also, within a family, the number of really bad matches is relatively small. In a non- 
related population, however, the chances of getting a bad match are exceedingly high. These 
may be the reasons why in nonrelated groups, but not in related groups, a significant 
improvement in the matching could be achieved following the criteria of leukocyte typing. 
DR. AMIEL: I would like to comment on the possibility of successfully selecting a donor 
to match the prospective recipient by phenotyping leukocyte antigens. Experiments in mice 
performed in our laboratory showed that, when bone marrow cells from more than one 
donor are transplanted into one recipient, those from the most compatible donor prevail 
and can be recovered some weeks after grafting. In a clinical case, four members of the 
family of a prospective recipient (father, mother, and two brothers of the mother) and two 
unrelated donors chosen from a list of about fifty volunteers on the basis of leukocyte 
typing (agglutination and cytotoxicity) served as bone marrow donors. Two months later, 
it was found .that the successful graft originated from one of the two unrelated donors. This 
observation indicates the validity of matching by leukocyte typing. As a second point I 
would like to mention that sometimes rejection crises of the kidney can be completely 
overcome in the absence of treatment. 
DR. STARZL: I appreciate very much hearing about the clinical case you mentioned. 
Concerning your second point, I think that one would not often see spontaneous revers- 
ability of rejection crises if it were not for the basic therapy with immunosuppressants. 
Recently, we did orthotopic liver transplantations in about 100 dogs using azathioprine as 
the sole method of therapy, and we found that one half of the animals went through a crisis 
in which serum bilirubin values went up and then came down spontaneously without the 
addition of further therapy. It would seem that rejection of transplanted organs is char- 
acterized by spontaneous remissions and exacerbations. 
DR. WITZ: Dr. Starzl, I wonder whether immunosuppression is the only possible 
mechanism for the effects of antilymphoid antisera on kidney transplantation. Is it possible 
that a phenomenon similar to passive immunological enhancement, as described by Kaliss, 
might occur in your system? 
DR. STARZL: I do not know the mechanism of the antilymphoid serum. Lymphopenia 
was not seen in a dog bearing a long-living liver graft. In some experiments antilymphoid 
globulin was given deliberately at  such low levels that it had no lymphopenic effect, and yet 
definite therapeutic results were obtained. In most animals treated with the serum, the host 
spleen and lymph nodes were actually hyperplastic. Therefore the notion that the anti- 
lymphoid serum must cause lymphopenia and lymphoid atrophy to be effective requires 
revision. 
DR. AMOS: The same sort of paradox is represented by the lack of correlation between 
lymphopenia and drug-induced immunosuppression. 
DR. HOLLAND: Dr. Starzl, renal donation is not without hazard to the donor. Has any 
technique of genetic matchings been helpful in improving cadaver kidney usefulness? 
DR. STARZL: A dialysis center could be established at  which a large number of patients 
could be typed, who could then be matched if a cadaveric donor became available. This is 
just a converse of what most centers are doing at  present in which a recipient is matched 
against a panel of donors. There are patients who have a great number of white cell antigens 
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and who are comparable, in the context of blood transfusion, to patients of AB blood type. 
They are "universal tissue recipients." We have done several cadaveric transplants start- 
ing 6 to 12 months ago into patients who are "universal recipients." Of these, only one 
has died. 
DR. REGELSON: In view of the fact that lymphohyperplasia occurs despite the immuno- 
suppressive treatments applied, have agents which produce lymphocytosis, for example, 
pertussis vaccine or thyrotropic hormone or thyroid hormones been tried? These could be 
tried in association with immunosuppressive drugs in attempts to see whether the lymphoid 
cells are still potentially functional or whether an increased immunosuppressive effect can 
be obtained. 
DR. STARZL: I t  has been suggested by Dr. Medawar that the mechanism of antilymphoid 
globulin may be similar to that of phytohemagglutinin, and that what the globulin does is to 
send the lymphoid tissue off "on a wild goose chase" with a lot of activity and no specificity. 
DR. TURK: Have you seen any signs of serum sickness in patients treated with horse 
antiserum? Did any of these patients develop eosinophilia? 
DR. STARZL: Some of the patients developed eosinophilia. We studied quantitatively 
the response of patients to horse proteins by determining the antihorse protein precipitin 
titers which rose from 1 : 2 to 1 : 16, which was the highest level seen. On a few occasions 
the antibody titer returned to normal levels during treatment. Hemagglutinin titers against 
sheep red cells rose to levels as high as 1 : 5 12 in patients who had no other sign of toxicity. 
The clinical toxicity seen included a local reaction at the site of serum injection which 
tended to be much more severe on the first than on subsequent injections. Out of twelve 
patients, one developed hives once, another became acutely hypertensive for about 30 
minutes, and a third one became hypotensive for about 10 or 15 minutes and developed air 
hunger. All these patients have subsequently received globulin on a number of occasions 
without recurrence of these effects. 
DR. TURK: The rise of antibody against sheep red cells observed by Dr. Starzl in patients 
treated with horse antisera might be due to Forssman antigen which may be present in 
horse globulin as well as on sheep cells. 
DR. MILGROM: Some explanation may be offered for the graft disease that Dr. Starzl 
described, namely, the lesions within the grafted, nonrejected kidney. I think that immuno- 
suppressive drugs save the graft from rejection but do not suppress significantly the forma- 
tion of humoral antibodies. These humoral antibodies, directed against transplantation 
antigens, cannot be detected in the circulation since they are removed by the kidney. This 
was quite clearly demonstrated in dogs in which the humoral antibody was completely 
removed within hours after they were regrafted with the kidney from the original donor. 
Also, in humans we could not observe humoral antibodies as long as the graft was present, 
but we detected them after surgical removal of the graft. It seems quite plausible that the hu- 
moral antibodies directed against transplantation antigens act as Masugi's antibody in com- 
bining with antigen within the grafted kidney and inducing pathologic changes. Another point 
I would like to make is in connection with the use of heteroimmune sera which contain anti- 
bodies against human antigens. As Dr. Starzl demonstrated, these antibodies are not lympho- 
cyte specific. They are just directed against man, as a species, and they combine with anti- 
gens on the cell surface. This type of antibody, from what is known, is a rather dangerous 
tool. I am far from criticizing Dr. Starzl's attempts, because without having anything better, 
he seems to be justified in trying this tool. I wonder whether this antilymphocytic serum does 
anything besides causing a depletion of lymphocytes. One could achieve a depletion of 
cannulation of lymphatics without running into the risks deriving from the use of sera which 
may be quite toxic for the recipient. 
DR. STARZL: I do not think one could achieve with lymphocyte depletion the same effect 
as that seen with the antilymphoid serum. I believe that the remarks you made on another 
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occasion deserve repeating, namely, that if the antiserum has any degree of specificity at  all 
it may be not because of immunologic specificity but because the lymphocyte represents a 
spectacular target. In another connection I would solicit Dr. Milgrom's comments about 
the humoral antibodies directed against the graft which have been found in almost all our 
patients after renal homotransplantation. 
DR. MILGROM: I am aware of Dr. Starzl's attempts to find humoral antibodies which 
are primarily being detected by using sheep erythrocytes in antiglobulin consumption 
techniques. Most likely, differences in procedures account for different experimental results. 
